HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    
Quote:
Login Free Membership
Search:

Analyst Blog  

Isis Pharma Maintains a Buy

Share
February 27, 2009 |Comments: 0
Recommended this article (0)

We are reiterating or rating on Isis Pharmaceuticals (ISIS) of a Buy and maintaining our price target of $22.

We believe that antisense technology represents an exciting and potentially revolutionary platform for developing therapeutic candidates to treat a wide margin of diseases. In our view, antisense as a platform is today where biologics were 10 years ago.

The company's leading candidates are mipomersen (w/ Genzyme, GENZ) for high cholesterol and ISIS-113715 for diabetes, along with several other proprietary and partnered programs for oncology, inflammatory disease, asthma, and viral infections. Our financial model forecasts sustained profitability in 2011.

Read the full analyst report on ISIS

 

More Zacks Resources

Market Summary Feb 10, 2012 09:38 am ET
DJIA 12760.17  -130.29 -1.01%
NASD 2898.94  -28.29 -0.97%
S&P 500 1338.75  -13.20 -0.98%
Partner Center